Many videos on the social media platform TikTok that are focused on obsessive thoughts about food include patient ...

Shivaji Dasgupta, an autonomous Brand Consultant, writes that India’s obsession with shortcuts risks turning a breakthrough ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

A U.S. federal judge upheld the FDA’s decision to remove Eli Lilly’s weight loss and diabetes drugs, Zepbound and Mounjaro, from the list of medicines in short supply, impacting the production ...

This news comes on the heels of Lilly’s first-quarter 2025 financial results. 2 According to the company, revenue during this quarter increased 45%. This growth was driven by Mounjaro and Zepbound.

Dairy brand Amul has once again struck the right chord with its latest topical poster - this time celebrating the much-talked-about debut of Shah Rukh Khan at the MET Gala 2025. Known for its ...

Lilly’s first-quarter revenue grew 45% as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose dramatically to reach $6.2 billion, up year over year from $2.3 billion. Separately ...

Seigerman agreed, saying that Eli Lilly is "continuing to perform where it matters." Zepbound and the company's diabetes drug Mounjaro now make up over half of U.S. GLP-1 prescriptions ...

A Lilly spokesperson said the court’s decision confirms that Mounjaro and Zepbound are not in shortage, and that "continuing to sell mass compounded products, including when referring to them as ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Meanwhile, the company continues to expand Mounjaro internationally. The drug is now available in 40 countries, and recently launched in India and Mexico. Lilly will continue to bring Mounjaro to ...